Two Patients with Advance-Stage Renal Cell Carcinoma Developed Sunitinib-Related Skin Toxicity

نویسندگان

  • Mehmet Cetinkaya
  • Ozgur Tanriverdi
  • Hasan Deliktas
  • Asude Kara
  • Yelda Dere
  • Hayrettin Sahin
چکیده

With the current treatment modalities like molecular targeted therapy, general survival rates have increased in patients with advanced-stage renal cell carcinoma. Sunitinib maleate is one of these drugs and its most frequently side effects are fatigue, diarrhea, hypertension, stomatitis, and hair hypo-pigmentation. Additionally, various dermatological side-effects may also be seen such as handfoot syndrome, a yellowish color change to the face, splinter hemorrhage, erythematous reactions on the trunk, facial edema, facial erythematous changes, alopecia, acneiform rash on the face and dysesthesia in the scalp. Although Sunitinib maleate-related scrotal skin toxicity is extremely rarely seen, it should not be forgotten that this side-effect can be easily managed. Herein, we report two cases with Sunitinib maleate-related scrotal skin toxicity, which were diagnosed with advancedstage renal cell carcinoma in this case report.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma

Sunitinib is a multiple tyrosine kinase receptor inhibitor that is approved for the treatment of metastatic renal cell carcinoma (RCC). However, neither an appropriate dose nor dosing schedule of sunitinib has yet been established for patients with metastatic RCC who are on hemodialysis. Here, we report on two hemodialysis patients who received sunitinib to treat metastatic RCC. Sunitinib was p...

متن کامل

Analysis of adverse events of sunitinib in patients treated for advanced renal cell carcinoma

INTRODUCTION Treatment of the metastatic stage of renal cell carcinoma is specific because classical chemotherapy is not applicable here. The treatment is mainly based on molecularly targeted drugs, including inhibitors of tyrosine kinases. In many cases the therapy takes many months, and patients often report to general practitioners due to adverse events. In this article, the effectiveness an...

متن کامل

The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.

OBJECTIVES The purpose of this study was to document the incidence and extent of cardiovascular toxicity among advanced renal cell carcinoma patients treated with newer targeted cancer agents. BACKGROUND The potential for targeted cancer agents to induce cardiovascular toxicity has been increasingly recognized, but the overall incidence and extent of toxicity have not been well characterized....

متن کامل

Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines.

BACKGROUND/AIMS This retrospective analysis compared progression-free survival (PFS) in 111 patients who developed or had preexisting hypertension with those who did not during treatment with second-line sunitinib. Secondary objectives included overall survival (OS) and safety. METHODS Patients with metastatic renal cell carcinoma (mRCC) received sunitinib 50 mg orally once daily in 6-week cy...

متن کامل

Acute Acalculous Cholecystitis in Patients With Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Report of Two Cases

Although sunitinib is associated with a variety of adverse events, cases of sunitinib-related acute cholecystitis have rarely been reported. We herein report two cases of sunitinib-related acute acalculous cholecystitis in patients with clear cell renal cell carcinoma. In both cases, the gallbladder was surgically removed because it was difficult to improve the patient's condition with the cess...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2017